breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiske midler - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
dogmatil 400 mg filmovertrukne tabletter
sanofi a/s - sulpirid - filmovertrukne tabletter - 400 mg
dolmatil 400 mg filmovertrukne tabletter
2care4 aps - sulpirid - filmovertrukne tabletter - 400 mg
dolmatil 400 mg filmovertrukne tabletter
orifarm a/s - sulpirid - filmovertrukne tabletter - 400 mg
firdapse (previously zenas)
serb sa - amifampridin - lambert-eaton myasthenic syndrom - andre narkotika stoffer - symptomatisk behandling af lambert-eaton myasthenisk syndrom (lems) hos voksne.
bisoprolol "teva" 10 mg tabletter
teva b.v. - bisoprololfumarat - tabletter - 10 mg
bisoprolol "teva" 5 mg tabletter
teva b.v. - bisoprololfumarat - tabletter - 5 mg
bisoprolol "stada" 10 mg filmovertrukne tabletter
stada arzneimittel ag - bisoprololfumarat - filmovertrukne tabletter - 10 mg
bisoprolol "stada" 5 mg filmovertrukne tabletter
stada arzneimittel ag - bisoprololfumarat - filmovertrukne tabletter - 5 mg
exelon
novartis europharm limited - rivastigmin - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatisk behandling af mild til moderat alvorlig alzheimers demens. symptomatisk behandling af mild til moderat svær demens hos patienter med idiopatisk parkinsons sygdom.